摘要
克罗恩病（CD）是肠道的慢性炎症，其特征是复发和缓解。 尽管CD的治疗选择有所进步，但仍有大量患者需要手术治疗难治性疾病或与疾病相关的并发症。 鉴于对于中度至重度CD患者广泛采用生物疗法，在需要进行肠外科手术时大量患者可能正在接受生物疗法：围手术期生物制剂的安全性非常重要 利益。 尽管可获得更多有关TNF拮抗剂和vedolizumab的临床数据，但缺乏IL 12/23抑制剂ustekinumab的安全性数据。 在这里，我们回顾了来自公开发表的文献的围手术期暴露于ustekinumab CD患者术后结局的可用数据。
关键词: Ustekinumab，克罗恩病，手术，慢性炎症，生物疗法，维多珠单抗。
[1]
Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012; 380(9853): 1590-605.
[http://dx.doi.org/10.1016/S0140-6736(12)60026-9] [PMID: 22914295]
[http://dx.doi.org/10.1016/S0140-6736(12)60026-9] [PMID: 22914295]
[2]
Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut 2011; 60(9): 1178-81.
[http://dx.doi.org/10.1136/gut.2010.234617] [PMID: 21610273]
[http://dx.doi.org/10.1136/gut.2010.234617] [PMID: 21610273]
[3]
Holubar SD, Dozois EJ, Privitera A, et al. Minimally invasive colectomy for Crohn’s colitis: a single institution experience. Inflamm Bowel Dis 2010; 16(11): 1940-6.
[http://dx.doi.org/10.1002/ibd.21265] [PMID: 20848480]
[http://dx.doi.org/10.1002/ibd.21265] [PMID: 20848480]
[4]
Lee RH, Efron DT, Tantry U, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair Regen 2000; 8(6): 547-53.
[http://dx.doi.org/10.1046/j.1524-475x.2000.00547.x] [PMID: 11208182]
[http://dx.doi.org/10.1046/j.1524-475x.2000.00547.x] [PMID: 11208182]
[5]
Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohn’s Colitis 2013; 7(11): 853-67.
[http://dx.doi.org/10.1016/j.crohns.2013.01.014] [PMID: 23523418]
[http://dx.doi.org/10.1016/j.crohns.2013.01.014] [PMID: 23523418]
[6]
Gionchetti P, Dignass A, Danese S, et al. ECCO Guidelines/Consensus Paper 3rd European evidence-based consensus on the diagnosis and management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohn’s Colitis 2017; 11(2): 135-49.
[7]
Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-tumor necrosis factor-α antibody therapy management before and after intestinal surgery for inflammatory bowel disease: A CCFA position paper. Inflamm Bowel Dis 2015; 21(11): 2658-72.
[http://dx.doi.org/10.1097/MIB.0000000000000603] [PMID: 26422516]
[http://dx.doi.org/10.1097/MIB.0000000000000603] [PMID: 26422516]
[8]
Yamada A, Komaki Y, Patel N, et al. Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol 2017; 112(9): 1423-9.
[http://dx.doi.org/10.1038/ajg.2017.201] [PMID: 28719595]
[http://dx.doi.org/10.1038/ajg.2017.201] [PMID: 28719595]
[9]
Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for crohn’s disease. J Crohn’s Colitis 2018; 12(4): 402-7.
[http://dx.doi.org/10.1093/ecco-jcc/jjx163] [PMID: 29220430]
[http://dx.doi.org/10.1093/ecco-jcc/jjx163] [PMID: 29220430]
[10]
Ferrante M, de Buck van Overstraeten A, Schils N, et al. Perioperative use of vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy. J Crohn’s Colitis 2017; 11(11): 1353-61.
[http://dx.doi.org/10.1093/ecco-jcc/jjx095] [PMID: 28981886]
[http://dx.doi.org/10.1093/ecco-jcc/jjx095] [PMID: 28981886]
[11]
Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367(16): 1519-28.
[http://dx.doi.org/10.1056/NEJMoa1203572] [PMID: 23075178]
[http://dx.doi.org/10.1056/NEJMoa1203572] [PMID: 23075178]
[12]
Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s Disease. N Engl J Med 2016; 375(20): 1946-60.
[http://dx.doi.org/10.1056/NEJMoa1602773] [PMID: 27959607]
[http://dx.doi.org/10.1056/NEJMoa1602773] [PMID: 27959607]
[13]
Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168(4): 844-54.
[http://dx.doi.org/10.1111/bjd.12214] [PMID: 23301632]
[http://dx.doi.org/10.1111/bjd.12214] [PMID: 23301632]
[14]
Fabiano A, De Simone C, Gisondi P, et al. Management of patients with psoriasis treated with biological drugs needing a surgical treatment. Drug Dev Res 2014; 75(Suppl. 1): S24-6.
[http://dx.doi.org/10.1002/ddr.21189] [PMID: 25381969]
[http://dx.doi.org/10.1002/ddr.21189] [PMID: 25381969]
[15]
Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 2015; 151(9): 961-9.
[http://dx.doi.org/10.1001/jamadermatol.2015.0718] [PMID: 25970800]
[http://dx.doi.org/10.1001/jamadermatol.2015.0718] [PMID: 25970800]
[16]
Shim HH, Ma C, Kotze PG, et al. Preoperative ustekinumab treatment is not associated with increased postoperative complications in Crohn’s disease: A Canadian multicentre case–control cohort study. J Can Assoc Gastroenterol in press
[http://dx.doi.org/10.1016/S0016-5085(17)32085-1]
[http://dx.doi.org/10.1016/S0016-5085(17)32085-1]
[17]
adedokun oj, xu z, gasink c, et al. pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease. Gastroenterology 2018; 154(6): 1660-71.
[http://dx.doi.org/10.1053/j.gastro.2018.01.043] [PMID: 29409871]
[http://dx.doi.org/10.1053/j.gastro.2018.01.043] [PMID: 29409871]
[18]
Janssen Biotech Inc. Available from:. http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/REMICADE-pi.pdf2017
Article Metrics
72
9
1